Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

@article{Rosenstock2008EffectsOT,
  title={Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.},
  author={Julio Rosenstock and James E Foley and Marc Rendell and Mona Landin-Olsson and Jens Juul Holst and Carolyn F Deacon and Erika Rochotte and Michelle A Baron},
  journal={Diabetes care},
  year={2008},
  volume={31 1},
  pages={30-5}
}
OBJECTIVE This study was conducted to determine the effects of vildagliptin on incretin hormone levels, islet function, and postprandial glucose control in subjects with impaired glucose tolerance (IGT). RESEARCH DESIGN AND METHODS A 12-week, double-blind, randomized, parallel-group study comparing vildagliptin (50 mg q.d.) and placebo was conducted in 179 subjects with IGT (2-h glucose 9.1 mmol/l, A1C 5.9%). Plasma levels of intact glucagon-like peptide 1 (GLP-1) and gastric inhibitory… CONTINUE READING
53 Citations
20 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes

  • J Rosenstock, MA Baron, RP Camisasca, F Cressier, A Couturier, S Dejager
  • Diabetes Obes Metab 9:175–185,
  • 2007

Efficacy and tolerability of vildagliptin in drug-naı̈ve patients with type 2 diabetes (T2DM) and mild hyperglycemia (Abstract)

  • WA Scherbaum, A Schweizer, +4 authors JE Foley
  • Diabetes 56 (Suppl. 1):A134,
  • 2007

Similar Papers

Loading similar papers…